Fig. 4: TCR clonotype analyses.
From: Clinical trial links oncolytic immunoactivation to survival in glioblastoma
a, The correlation between the change in tumour T cell fraction (after versus before CAN-3110 treatment) and survival after CAN-3110 treatment. The T cell fraction is the fraction of nucleated cells that are T cells on the basis of TCRβ DNA-seq analysis (see the ‘Definition of TCR based metrics’ section in the Supplementary Methods). b, The correlation between post-CAN-3110 tumour TCR productive entropy (Supplementary Methods) and survival. A higher entropy indicates a greater diversity of TCRβ rearrangements. n = 18 interventions and 17 patients. For a and b, three participants were excluded (two who survived longer than 1 year, and one who survived less than 1 year) with <200 ng of gDNA. n = 18 interventions and 17 patients. Extended Data Fig. 9b,c shows analyses with all patients, regardless of the amount of gDNA collected. c, The correlation between the change in PBMC TCR clonotype fraction (after versus before CAN-3110 treatment) and survival after CAN-3110 treatment. n = 21 interventions and 20 patients. For a–c, Pearson’s r correlation coefficients and P values (two-sided, based on t-distribution) are shown above the plots. d, Kaplan–Meier survival analysis based on an increase (change > 0) or decrease (change < 0) in PBMC productive Simpson’s clonality (Supplementary Methods) after CAN-3110 treatment. HRincreased = 2.79 (95% CI = 1.08–7.21), P = 0.034 (two-sided Cox proportional-hazard test). Higher clonality indicates a lower diversity of TCRβ rearrangements.
